26.8 C
New York
Thursday, July 3, 2025

Tag: AstraZeneca

INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. (TEM) Investors with Substantial Losses Have Opportunity to Lead Class Action...

SAN DIEGO, July 02, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, all dates inclusive (the “Class Period”), have until August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI as well as certain of Tempus AI’s top executives with violations of the Securities Exchange Act of 1934.

TEMPUS AI SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead...

NEW YORK and NEW ORLEANS, July 01, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company’s shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.

DEADLINE ALERT for RCKT, DDD, TEM: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

BENSALEM, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line...

— Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum-based chemotherapy —

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

TEMPUS AI SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead...

NEW YORK and NEW ORLEANS, June 24, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company’s shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.

BAFF- and APRIL-targeted Therapies Market Sees Surge in Activity Amid Rising Autoimmune Disease Burden | DelveInsight

The BAFF- and APRIL-targeted therapies market is experiencing steady growth driven by the rising prevalence of autoimmune diseases such as systemic lupus erythematosus (SLE),...

BAFF- and APRIL-targeted Therapies Market Sees Surge in Activity Amid Rising Autoimmune Disease Burden | DelveInsight

The BAFF- and APRIL-targeted therapies market is experiencing steady growth driven by the rising prevalence of autoimmune diseases such as systemic lupus erythematosus (SLE),...

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vestis, PepGen, and Tempus and Encourages Investors to Contact...

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Vestis Corporation (NYSE:VSTS), PepGen, Inc. (NASDAQ: PEPG), and Tempus AI, Inc. (NASDAQ: TEM). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Questex’s Fierce Pharma Unveils Powerhouse Conference Program for the Inaugural Fierce Pharma Week, Where Pharma’s Future Takes Shape

Unites Pharma Marketing, PR & Communications, New Product Planning & Commercialization, and Medical Affairs Communities; Thought Leaders from AbbVie, AstraZeneca, BMS, GSK, Johnson & Johnson, NBCUniversal, Pfizer, Takeda and More Deliver Unparalleled Education

INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit...

SAN DIEGO, June 21, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, both dates inclusive (the “Class Period”), have until August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI and certain of Tempus AI’s top executives with violations of the Securities Exchange Act of 1934.

HER2-low Cancers Market Set to Register Immense Growth at a CAGR of 9.4% During the Study Period (2020-2034) | DelveInsight

The future of the HER2-low cancer treatment market is poised for significant transformation, driven by the approval of ENHERTU and the advancement of other...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsAstraZeneca